medRxiv preprint doi: https://doi.org/10.1101/2021.12.23.21268085; this version posted December 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in percetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

1 External validation of six clinical models for prediction of unknown chronic kidney

2 disease in a German population

- 3
- 4 Susanne Stolpe, MSc
- 5 University Hospital Essen, Institute for medical informatics, biometry and epidemiology,
- 6 Essen, Germany
- 7 Hufelandstr. 55, D-45147 Essen
- 8 Tel: +49 201 723 77231
- 9 <u>Susanne.stolpe@uk-essen.de</u> (corresponding author)
- 10
- 11 Bernd Kowall, PD
- 12 University Hospital Essen, Institute for medical informatics, biometry and epidemiology,
- 13 Essen, Germany
- 14
- 15 Denise Zwanziger, PhD
- 16 University Hospital Essen, Institute for medical informatics, biometry and epidemiology,
- 17 Essen, Germany
- 18
- 19 Mirjam Frank, PhD
- 20 University Hospital Essen, Institute for medical informatics, biometry and epidemiology,
- 21 Essen, Germany
- 22
- 23 Karl-Heinz Jöckel, Prof
- 24 University Hospital Essen, Institute for medical informatics, biometry and epidemiology,
- 25 Essen, Germany
- 26
- 27 Raimund Erbel, Prof
- 28 University Hospital Essen, Institute for medical informatics, biometry and epidemiology,
- 29 Essen, Germany
- 30
- 31 Andreas Stang, Prof
- 32 University Hospital Essen, Institute for medical informatics, biometry and epidemiology,
- 33 Essen, Germany
- 34 School of Public Health, Department of Epidemiology, Boston University, Boston, USA
- 35
- 36 Word count abstract: 209
- 37 Word count article 2.886
- 38

medRxiv preprint doi: https://doi.org/10.1101/2021.12.23.21268085; this version posted December 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

- 39 Abstract
- 40

41 Background

42 Chronic kidney disease (CKD) is responsible for large personal health and societal burdens.

43 Screening populations at higher risk for CKD is effective to initiate earlier treatment and

- decelerate disease progress. We externally validated clinical prediction models for unknown
 CKD that might be used in population screening.
- 45 CKD that might be used in population 46

47 Methods

We validated six risk models for prediction of unknown CKD using only non-invasive parameters. Validation data came from 4,185 participants of the German Heinz-Nixdorf-Recall study (HNR), drawn in 2000 from a general population aged 45-75 years. We estimated discrimination and calibration using the full model information, and calculated the diagnostic properties applying the published scoring algorithms of the models using various thresholds for the sum of scores.

53 the sum of score

55 **Results**

The risk models used four to nine parameters. Age and hypertension were included in all models. Five out of six c-values ranged from 0.71 to 0.73, indicating fair discrimination. Positive predictive values ranged from 15% to 19%, negative predictive values were >93% using score thresholds that resulted in values for sensitivity and specificity above 60%.

60

61 **Conclusions**

62 Most of the selected CKD prediction models show fair discrimination in a German general 63 population. The estimated diagnostic properties indicate that the models are suitable for

64 identifying persons at higher risk for unknown CKD without invasive procedures.

66 Background

Prevalence of chronic kidney disease (CKD), defined by a chronically impaired renal function, 67 is growing worldwide and a challenge for public health. In Germany, prevalence of a decreased 68 renal function is up to $11.5 \ \%^1$. Patients with CKD are at higher risk of cardiovascular 69 comorbidities, hospitalization, end stage renal disease (ESRD) and premature death². As a CKD 70 71 cannot be cured, treatment aims at monitoring CKD risk factors - especially hypertension and 72 blood glucose - to decelerate its progression and to prevent the incidence of secondary diseases³. Early diagnosis of a prevalent CKD can support these efforts. Despite the high 73 prevalence and relevance for public health, public and patient awareness for CKD is low. The 74 main reason for the low awareness is that CKD remains asymptomatic until reaching more 75 76 serious stages. Moreover, a declining renal function is a physiological sign of older age, which often hinders physicians to designate an impaired renal function in older age as CKD.^{4,5} 77

In Germany, fewer than 50% of patients with CKD -even with hypertension or cardiovascular

79 disease - knew about their condition $^{6.7}$. In the USA, CKD unawareness is even more

80 prevalent⁸. The high unawareness for CKD is astonishing, as regular monitoring of renal

function should be mandatory for patients with hypertension, diabetes or of older $age^{3,9-11}$.

82 However, in general practice, even in patients with diabetes or hypertension, renal function,

83 blood glucose or blood pressure are not regularly monitored ^{12,13} and risk factors are

84 inadequately controlled 14,15 .

According to Tonelli et al. most of the principles for population screening -formulated in a Delphi process among experts- fit to screening for CKD¹⁶. Screening for CKD has already been shown to be cost-effective in detecting unknown cases in population subgroups at higher risk for CKD ¹⁷⁻¹⁹. In a simulation study, it was shown that CKD prediction scores can be costeffectively used to initially identify people at higher risk for incident CKD, and to screen these subsequently for CKD by testing for albuminuria ²⁰. Prediction models suitable for identifying

people at higher risk for CKD should be easy to apply, preferentially using non-invasive
parameters only. Many CKD risk models of different complexity have already been developed
– regarding the prediction of incidence, prevalence and progression to ESRD ²¹. However,
missing external validation might frequently hinder the implementation into practice ^{22,23}.

95 The aim of this study was, to externally validate prediction models, that estimate the probability
96 of a prevalent unknown CKD using non-invasive parameters only in a German general
97 population.

98 Material and methods

99 *CKD prediction models*

Starting with a review on CKD prediction models from 2012²¹, we searched the literature for 100 101 further models that comprise only clinical information for estimating the risk of prevalent CKD. We identified five models that meet these criteria ²⁴⁻²⁸. Among these, Bang reported two 102 versions of a model developed in the same population: SCORED and modified SCORED 103 104 (Table 1). For these models, a scored version as self-completing questionnaire is published ²⁵. The intercepts for the SCORED models and the models by Kwon and Thakkinstian had not 105 been published. For the SCORED and the Kwon model, we were able to get the missing 106 information about the intercept from the authors. For the Thakkinstian model we used the 107 intercept published in a validation study ²³. As the Kearns model estimated an unrealistic high 108 109 risk for CKD in our validation population, we contacted the author and learned that the ageparameter should have had been centered (by subtracting the value 46.72) prior to the division 110 of age by 10). This had not been reported in the manuscript. Further, no cutoffs or scoring rule 111 112 for the Kearns-Model had been described, although sensitivity and specificity information had been estimated in the paper. As we could get no information on the applied rules for scoring 113

- the model parameters, we were not able to estimate the diagnostic properties of the Kearns
- 115 model in our validation cohort.
- 116 The number of parameters used in the CKD prediction models ranged from four (Thakkinstian)
- to nine (SCORED) (Table 1). Age and hypertension were the only predictors used in all models.
- 118 The Kearns model relies heavily on age, using age as interaction term with other parameters as
- 119 well. History of kidney stones and history of ischemic heart disease were used only once.

121 Table 1. Identified prediction models for CKD: included parameters and their coefficients.

	Bang SCORED	Bang "modified SCORED"	Kearns	Kshirsagar	Kwon	Thakkinstian
No of parameters	9	7	5	8	7	4
Intercept	-5.40 ^a	-5.38ª	-3.63	-3.30	-6.53ª	-2.8 ^b
Age (yrs)	1.55 [50-59]	1.55 [50-59]	1.075 [Per 10 yrs ^c]	0.63 [50-59]	1.16 [50-59]	0.6 [50-59]
	2.31 [60-69]	2.29 [60-69]	-0.01 [age ² /10 yrs ^c]	1.33 [60-69]	1.91 [60-69]	1.4 [60-69]
	3.23 [>=70]	3.29 [>=70]	0.104 [age < 50]	1.46 [>=70]	2.71 [>=70]	2.1 [>=70]
Sex – Female	0.29	0.34	0.73	0.13	0.4	
Anemia	0.93			0.48	0.94	
Hypertension	0.45	0.47	0.74	0.55	0.48	0.8
			+ age <50: 0.56			
Diabetes	0.44	0.47		0.33	0.73	0.9
schemic heart disease or stroke (Hx)*	0.59	0.67		0.26	0.60	
Heart failure (hx)	0.45	0.51	0.86	0.50		
			CHF + age <50: 0.29			
schemic heart disease (Hx)			0.51			
			+ age<50: 0.13			
Peripheral vascular disease (Hx)	0.74		-	0.41		
Proteinuria	0.83	0.88			0.48	
Kidney stones (Hx)						1

a Intercept according to personal information by H. Bang.

b Intercept estimated using the prevalence of CKD in the validation population

124 c age per 10 yrs = (age -46.72) / 10yrs

126 Validation population

We used the German Heinz Nixdorf Recall Study (HNR), a population based cohort, ²⁹ for
external validation. Baseline data from 4,814 participants drawn from the general population
aged 45-75 years in 2000 were available. We included all participants with a valid measurement
of serum creatinine (N=4,789).

131 Measurement of variables

132 In HNR, all laboratory data had been analyzed centrally in the laboratory of the university hospital of Essen. Serum creatinine (according to Jaffé) was determined on a Siemens 133 Healthcare Diagnostics ADVIA Chemistry. Serum creatinine was not standardized to isotope 134 135 dilution mass spectrometry. Hypertension was defined as either a blood pressure of at least 140mmHg systolic or at least 90mmHg diastolic or taking antihypertensive medication. Blood 136 pressure cut-offs were selected according to the cut-offs used to define hypertension in the 137 validated risk models. Diabetes was defined according to the respective definitions used in the 138 risk models: either self-reported prevalent diabetes ^{25,26} or using a combination of known 139 diabetes or taking antidiabetic drugs ^{27,28}. Albuminuria was defined as albumin/creatinine ratio 140 (ACR) ≥30mg/dl. In all models except the Kwon model, anemia was coded if hemoglobin levels 141 were <12 g/dl. In the Kwon model, the threshold for hemoglobin was <12 g/dl for women and 142 <13 g/dl for men. Peripheral vascular artery disease was defined according to clinical 143 information. 144

145 Definition of chronic kidney disease in development and validation populations

146 In all validated risk models, CKD was defined as an estimated glomerular filtration rate (eGFR)

 $147 \qquad < 60 ml/min/1.73 m^2 \ calculated \ by the \ Modification \ of \ Diet \ in \ Renal \ Disease \ (MDRD) \ equation.$

- 148 All models had been developed to estimate the risk of unknown prevalent CKD stages 3 or
- 149 more. Therefore, we defined CKD as eGFR <60ml/min/1.73m² accordingly. We used the CKD-

Epi equation for calculating eGFR, as recommended by the Kidney Disease Improving Global Outcomes (KDIGO) ³⁰. In Germany, the CKD-Epi equation is widely used to report eGFR with laboratory results. As sensitivity analysis, we calculated the eGFR with the MDRD and the new Full-Age-Spectrum (FAS) equation (equations listed in supplement S2+S3) ³¹. We used the respective creatinine-based equations, because cystatin c measurements are not widely available in general practice.

156 Handling of missing values

We did a complete case analysis regarding all predictors used in the identified models, leaving 4,185 participants in HNR. The Thakkinstian score was validated in a subsample of HNR with information on the parameter 'history of kidney stones' that is used in this model only (N=3,433).

161 Statistical analysis

162 The models' discrimination was estimated by the c-value and the Tjur coefficient ³². The Tjur 163 coefficient is the difference between the mean predicted probability in cases and in non-cases. 164 The higher this difference the better the discriminative ability of a score. Calibration was 165 assessed graphically.

166 As measures for overall performance, we estimated the mean average prediction error (MAPE) and the Scaled Brier Score ^{23,32}. MAPE averages the deviations between the prediction (ranging 167 between 0 and 1) and the respective true value of zero or 1. The smaller the MAPE, the better 168 169 the prediction. The Scaled Brier Score is calculated by the squared difference between the prediction and the true value of outcome (=Brier Score) divided by the product of the mean 170 prediction value and 1- mean prediction value ³³. It ranges from 0 to 1 representing 0% to 100% 171 and is similarly interpreted as Pearson's R², indicating the rate of variability explained by the 172 model. 173

- 174 We estimated sensitivity, specificity and predictive values of the models after scoring the model
- parameters using the cut-offs reported by the authors. The optimal threshold for the validation
- 176 population was identified with the Youden index.
- 177 Additionally, we calculated the rate of expected to observed cases (E/O-proportion) for the
- 178 thresholds used. An E/O-proportion close to 1 indicates agreement between the number of
- 179 expected cases according to the models' cut-offs and observed cases, an E/O-proportion >1
- 180 indicates overestimation of CKD risk.
- 181 All statistical calculations were done using SAS 9.4.
- 182

183 Table 2. Characteristics of the validation and development populations of the CKD risk models (means and standard deviation (SD) or percent (%)).

			Development populati	ment populations for identified CKD prediction models			
	Heinz-Nixdorf-	Bang (SCORED, modified	Kearns 2013	Kshirsagar 2008	Kwon 2011	Thakkinstian 2011	
	Recall-Study	SCORED) 2007					
Country	Germany	USA, 72% white	UK, 30% white, 53% unknown	USA, 78% white	Korea	Thailand	
Size of population (N)	4,185	8,530	743,935	9,470	6,565	3,459	
CKD defined by	GFR<60	GFR<60	GFR<60	GFR<60	GFR<60	KDIGO CKD1-5	
Prevalence of CKD	8.6% (MDRD) 9.2% (CKD-Epi)	5.4% (MDRD)	6.8% (MDRD)	16.9% (MDRD)	4.6% (MDRD)	17.5 (CKD1-5 <i>,</i> MDRD)	
Handling of missings	Excluded	Excluded	Missing BP: no hypertension	Not reported	Excluded	Not reported	
emale	50.5%	52%	50%	56%	50%	54.5%	
Age, mean (SD)	59.6 (7.8)	46.0 (31.4)	46.7 (18.2)	57 (9)	44.2 (32.4)	45.2 (46.5)	
Age, range	45-75	20-85	≥18	45-64	≥19	≥18	
3MI, mean (SD)	27.8 (4.6)	28.0 (12.9)	-	27 (5)	23.6 (8.1)	24.0 (11.8)	
Smoking	23.3%	20%	20%	10%	27.5ª	35.9%	
Diabetes	7.9%	8%	5%	9%	8.3% ^b	11.9%	
Hypertension	59.2%	34%	15%	36%	22.5%	27.5%	
schemic heart disease or stroke	6.9%	4.9%	2% stroke, 4% IHD	8%	3.2% (IHD or stroke)	3.4% (heart disease)	
Heart failure	3.5%	2.1%	1%	0.7%	-	-	
Proteinuria	1.7%	10%	-	-	10.3%	-	
PVD	2.3%	2.7%	1%	4%	-	-	
Kidney stones	12.0% (N=3,398)	-	-	-	-	5.0%	
Serum creatinine nean (SD)	0.93 (0.2)	0.89 (0.4)	-	0.8 (0.2)	0.9 (8.1)	1.1 (1.18) male, 0.8 (1.18) female	
eGFR, mean (SD)	79.1 (17.6) (CKD-Epi)	94.0 (48.9) (MDRD)	-	-	85.9 (56.7) (MDRD)	-	
Anemia	, 2 1% (Hh <12)	2 7% ^c	-	-	8.1%	-	

184 BP: blood pressure; CKD: chronic kidney disease; CVD: cardiovascular disease; IHD: ischemic heart disease; KDIGO: Kidney Disease Improving Global Outcomes; MDRD:

185 modification of Diet in Renal Disease; PVD: peripheral vascular disease

a: smoking defined as: >5 packs life time or current.

b: diabetes defined as: glucose ≥126 or anti-diabetic medication or insulin therapy.

188 c: anemia defined as: treatment of anemia.

189 d: history of bypass operation used as surrogate for heart failure.

Results 191

Validation of identified risk models in the German HNR study 192

- Compared to the development populations of the validated risk models, the participants in the 193
- 194 HNR study were older (mean age 59.6 compared to 44.2 to 57 years), and reported hypertension
- more often (59% compared to 15 to 36%) (Table 3). Prevalence of CKD in HNR calculated by 195
- the MDRD-equation was 8.6%. It was higher than in the development populations of the Bang 196
- (SCORED) (5.4%), Kearns (6.8%) and Kwon (4.6%) models. In the US based population used 197
- 198 for deriving the Kshirsagar Score, CKD prevalence was 16.9%. Thakkinstian reported a
- 199 prevalence of 17.5%, however, in contrast to the other studies, CKD here comprises CKD stages

200 1-5.

The mean estimated probability of prevalent CKD differed strongly and ranged from p=0.025 201 (Kwon) to 0.317 (Thakkinstian) (Table 3). 202

Table 3. External validation of identified models to predict unknown CKD; validation data set: Heinz Nixdorf Recall study (Germany). CKD is defined as eGFR

205 <60ml/min/1.73m² using CKD-Epi equation for calculating eGFR. Measures presented with standard deviation (SD) or 95% confidence intervals (CI).

Characteristics	SCORED	Modified SCORED	Kearns	Kshirsagar	Kwon	Thakkinstian ^a
Range of scoring points	[0-12]	[0-10]	n.a.	[0-9]	[0-10]	[0-16]
eGFR equation in development	MDRD	MDRD	MDRD	MDRD	MDRD	MDRD
AUC in development (validation) set	0.88	0.87	0.90	0.69	0.83	0.77
Results of validation in HNR						
Participants in HNR	4,185	4,185	4,185	4,185	4,185	3,433
Mean prediction (SD)	0.084 (0.092)	0.087 (0.093)	0.148 (0.126)*	0.149 (0.081)	0.025 (0.029)	0.317 (0.189)
Area under the curve (AUC, 95% CI)	0.72 (0.70; 0.75)	0.73 (0.70; 0.75)	0.73 (0.71; 0.76)	0.71 (0.69; 0.74)	0.72 (0.70; 0.75)	0.67 (0.64; 0.70
Score performance in HNR						
Tjur coefficient ¹ (95%-Cl)	0.063	0.063	0.116	0.062	0.020	0.124
	(0.055- 0.071)	(0.055; 0.071)	(0.104; 0.129)	(0.053; 0.070)	(0.018; 0.023)	(0.102; 0.147)
MAPE ² (SD)	0.148 (0.24)	0.150 (0.24)	0.193 (0.21)	0.203 (0.20)	0.108 (0.27)	0.329 (0.20)
Brier Scaled ³ (%)	12.0	11.6	2.7	7.3	38.0	4.2
Examples of predicted risks for CKD						
(characteristics of ficticious persons)						
w, 65 yrs with hypertension and IHD	30%	17%	39%	26%	4%	25%
w, 75 yrs with hypertension, DM, proteinuria and anemia	68%	68%	52%	15%	15%	62%
m, 57 yrs with hypertension, DM, HF	8%	8%	16%	2%	2%	27%
m. 72 yrs with DM and proteinuria	29%	29%	15%	18%	7%	43%

206 1 Tjur coefficient of discrimination= difference in the mean prediction for cases and non-cases; better with larger values

207 2 MAPE = Mean average prediction error; better with small values

208 3 Brier Scaled = comparable to R²; better with larger values

209 Discrimination

Discrimination of all models but in the Kshirsagar model was lower in HNR compared to the
development data sets (Table 3). C-values ranged from 0.67 (Thakkinstian) to 0.73 (modified
SCORED) using CKD-EPI equation for defining CKD. With MDRD equation, c-values were
<0.7 for all scores. The FAS equation yielded a better discrimination (c-values 0.74-0.80) (see
supplement table S4). The Tjur-coefficient was largest and indicated best discrimination of
prediction for the Thakkinstian score (0.124) and the Kearns model (0.116).

216 *Calibration*

The calibration plots showed reasonable fit only with the Bang models (SCORED, modified SCORED). CKD risk was overestimated in persons with lower CKD risk and overestimated in persons with higher risk. Risk of unknown CKD was generally overestimated by the Kearns, Kshirsagar and Thakkinstian model. The Kwon model underestimated the probability of unknown CKD. Calibration to the HNR population was poor in all but the SCORED models (see supplementary file).

The Kwon score yielded the smallest mean average prediction error with 0.108 compared to the Thakkinstian score resulting in the largest MAPE with 0.329. The Brier Scaled which can be interpreted as R² indicated that the Kwon score prediction fitted best to the population.

Applying the published scoring rules for the models to the HNR study, the E/O-proportion depended strongly on the eGFR equation used. For example, using a threshold of six points, the 'modified SCORED' had an E/O-proportion of 1.17 (95%-CI: 1.06; 1.28) with the CKD-Epi equation, 1.55 (1.42; 1.68) with the MDRD and 0.91 (0.84; 0.99) with the FAS equation (supplement table 4, S4).

231 *Diagnostic criteria*

Thresholds of the scored models that resulted in a sensitivity >60% and specificity >60% (five points for the Bang and the Kwon models, four points for the Kshirsagar model and 7 points for the Thakkinstian model) resulted in positive predictive values (PPV) between 15% and 19%. Negative predictive values (NPV) were similar for all models independent of a chosen threshold and ranged between 93% and 95% (Tab. 4). Using the FAS-equation yielded the highest sensitivity and specificity for all thresholds compared to the CKD-EPI or MDRD equation (see supplement table S3a/b).

239 Tab. 4 Diagnostic criteria of validated models for various thresholds (sensitivity, specificity and predictive values

240 as well as proportions of expected to observed cases with 95%-confidence intervals) for CKD. CKD defined as

241 eGFR <60m/min/1.73m² calculated with CKD-Epi equation; CKD prevalence 9.2%.

Model				Predic	tive values	Expected/Observed	
		Sensitivity	Specificity	Positive Negativ		re CI)	
SCORED					-0	- /	
	4	84.9	44.4	13.4	96.7	6.33 (6.09; 6.59)	
!	5	61.0	72.5	18.4	94.8	3.32 (3.14; 3.51)	
	6	30.6	90.3	24.3	92.8	1.26 (1.15; 1.38)	
	7	11.4	97.4	13.5	96.6	0.37 (0.32; 0.44)	
Modified SCOR	ED						
	4	84.4	45.3	13.5	96.6	6.24 (6.00; 6.50)	
!	5	60.8	73.4	18.8	94.9	3.24 (3.06; 3.42)	
	6	29.1	91.1	24.9	92.7	1.17 (1.06; 1.28)	
	7	9.1	97.9	31.0	91.4	0.29 (0.24; 0.33)	
Kshirsagar							
:	3	84.2	44.4	13.3	96.5	6.33 (6.09, 6.59)	
	4	60.8	72.8	18.5	94.8	3.29 (3.12, 3.48)	
!	5	29.9	90.7	24.6	92.7	1.22 (1.11; 1.33)	
Kwon							
	4	84.7	45.2	13.5	96.7	6.26 (6.01; 6.51)	
!	5	59.7	73.7	18.7	94.8	3.20 (3.02; 3.38)	
(6	27.0	91.6	24.5	92.5	1.10 (1.00; 1.21)	
-	7	6.2	98.6	30.4	91.2	0.21 (0.16; 0.26)	
Thakkinstian							
(6	82.9	45.7	13.4	96.3	6.19 (5.94, 6.44)	
	7	69.9	58.2	14.5	95.0	4.83 (4.61, 5.05)	
:	8	43.9	81.0	18.9	93.4	2.32 (2.17, 2.48)	
9	9	41.8	83.8	20.8	93.4	2.02 (1.88, 2.16)	
10	0	38.7	866	22.6	93.3	1.71 (1.59; 1.85)	
1	1	28.8	90.8	24.2	92.7	1.19 (1.09; 1.31)	

243 **Discussion**

We externally validated six prediction models which estimate the probability for prevalent unknown CKD without any laboratory measurement. Most models yielded c-values of about 0.72 in the German HNR validation cohort. The calibration to the validation data set was reasonable only for the Bang (SCORED) models. A PPV of about 19% in a general population as estimated with all models but the Thakkinstian model indicates a good suitability as tools to identify patients at higher risk for whom further CKD diagnostic would be advisable.

250 Current use of risk models in CKD

Only few existing CKD prediction models are in use, such as the Kidney-Failure-Risk-Equation for prediction of renal failure. ^{34,35}. To prevent progression to serious consequences of CKD such as ESRD or cardiovascular diseases, early diagnosis of CKD is necessary. Due to the asymptomatic progress of the disease even patients in later stages of CKD are often undiagnosed and therefore untreated ⁸

Contrasting to screening for CKD in the general population, case finding in populations at higher risk has been proven cost-effective 36,37 . Existing CKD risk models have not yet been applied in programs aiming at identifying persons at higher risk for CKD. 18,38 . The Kshirsagar and the SCORED model were used in a simulation study that proved cost-effectiveness in identifying persons for screening for early stages of CKD 20 , SCORED was evaluated as screening tool for CKD in a small number of participants (N=172) as alternative to regular CKD screening protocols 39 .

Missing external validation of published CKD risk models can hinder clinical implementation. The SCORED, the Kwon-, Khirsagar- and the Thakkinstian- model have already been externally validated in 2016 in a UK population, but not with regard to the probability of prevalent CKD ²². Also, models using parameters that are either unfamiliar, unusually scaled,

complicated to calculate or costly to collect (e.g. genetic information) ⁴⁰ or that do not reflect the general opinion in clinic about risk factors have a low probability of being used in clinical routine. ^{41,42}. Most of the identified models comprise familiar predictors which reflect the current knowledge about CKD risk factors. Only the Kearns and the Thakkinstian model do not use diabetes or sex for CKD prediction– parameters which usually would be regarded as relevant for estimating the risk for CKD.

273 Validation results

Although the number and type of parameters used in the identified models differed, all but the 274 Thakkinstian model showed fair discriminative properties in the HNR cohort with c-values 275 ranging from 0.72 - 0.74. These c-values can be judged as satisfactory regarding the non-276 invasive and dichotomous nature of their predictors that facilitate potential implementations. 277 278 Taking the small age range of the HNR cohort compared to the development populations of most of the validated scores into account, c-values could have been expected to be lower than 279 in validation populations with full-age-spectrum ⁴³ as, within a small age-range, it is more 280 difficult to discriminate cases and non-cases when age is the most relevant prediction factor. 281

Calibration plots revealed a slight underestimation of CKD risk for the two Bang models. For all other models, calibration was poor. We recommend a re-calibration of the intercept ⁴⁴ if the estimated probabilities are of interest in regard to a clinical implementation of a model. In our estimation of the diagnostic properties we relied on the sum of scoring points for the parameters.

286 Potential implementation of the risk models

As the selected models do not use any laboratory or genetic information to estimate the risk for a prevalent CKD, these models can be used in screening scenarios where laboratory or genetic information would be too difficult or too expensive to get. Using the scoring rules for the models regarding the answers to the model parameters would enable to implement these models as self-

completing check-list tool for patients which can easily be evaluated in a screening scenario⁴³. However, acceptance of a prediction model is dependent on its face validity which means that the model parameters describe known risk factors. The validity of the Thakkinstian model without consideration of sex or of the Kearns model which does not imply diabetes might be questioned by physicians. On the other hand, proteinuria as a known risk factor is included in the SCORED and the Kwon model, but whether patients know for sure whether they had blood in their urine can be doubted.

298 Nevertheless, in a German general population, the modified SCORED and the Kwon model had good external validity and diagnostic properties. We think, that both models are suitable to 299 300 identify people at higher risk for CKD at low cost if implemented as web based tool or distributed as paper questionnaire on information leaflets for example in public places or at 301 health institutions. People who learn that they have a higher risk for CKD according their 302 303 answers to the questionnaire may inform their GP who can decide to initiate further CKD diagnostic. We think this pragmatic approach can contribute to higher awareness for CKD, 304 leading to earlier diagnosis and treatment. 305

306 Strengths

The HNR cohort is of high data quality and has been the base for many publications so far. All relevant parameters of the models have been available for the external validation. To our knowledge we are the first to externally validate prediction models for unknown CKD.

310 *Limitations*

We did not intend to do a systematic review on all CKD models suitable for risk estimation for unknown CKD. Therefore it might be possible that we did not include all existing model. However, to our knowledge, we were the first to evaluate all the selected models in regard to

their ability to predict prevalent CKD. We think that we herewith support potentialimplementations of these models.

- 316 The MDRD equation used in our sensitivity analyses has its weakness in a limited validity with
- eGFR levels >60ml/min/1.73m². This however does not affect our validation results, as all
- models estimate the risk for CKD stage 3 or more which is defined by lower eGFR levels.

319 Conclusions

External validation of risk models for unknown CKD yielded fair discrimination in a German population-based cohort. Calibration to the data was satisfactorily only for some scores. Diagnostic properties show that the models can be useful in screening scenarios to identify people at higher risk for CKD. As only non-invasive parameters are used, they can easily be

324 implemented as tool for patient self-assessment of CKD risk.

326 Funding

- 327 The authors thank the Heinz Nixdorf Foundation (Chairman: Martin Nixdorf; Past Chairman:
- 328 Dr jur. Gerhard Schmidt (†)), for their generous support of this study. Parts of the study were
- also supported by the German Research Council (DFG) (DFG project: EI 969/2-3, ER 155/6-
- 1;6-2, HO 3314/2-1;2-2;2-3;4-3, INST 58219/32-1, JO 170/8-1, KN 885/3-1, PE 2309/2-1,
- and SI 236/8-1;9-1;10-1), the German Ministry of Education and Science (BMBF project:
- 332 01EG0401, 01GI0856, 01GI0860, 01GS0820_WB2-C, 01ER1001D, and 01GI0205), the
- 333 Ministry of Innovation, Science, Research and Technology, North Rhine-Westphalia
- (MIWFT-NRW), the Else Kröner-Fresenius-Stiftung (project: 2015_A119) and the German
- 335 Social Accident Insurance (DGUV project: FF-FP295). Furthermore, the study was supported
- by the Competence Network for HIV/AIDS, the deanship of the University Hospital and
- 337 IFORES of the University Duisburg-Essen, the European Union, the German Competence
- 338 Network Heart Failure, Kulturstiftung Essen, the Protein Research Unit within Europe
- 339 (PURE), the Dr Werner-Jackstädt Stiftung, and the following companies: Celgene GmbH
- 340 München, Imatron/GE-Imatron, Janssen, Merck KG, Philips, ResMed Foundation, Roche
- 341 Diagnostics, Sarstedt AG&Co, Siemens HealthCare Diagnostics, and Volkswagen
- 342 Foundation. The study was funded by DFG within framework of TRR 296 LocoTact (DFG
- 343 project: 424957847).

344 Ethics approval and consent to participate

The Heinz-Nixdorf-Study has been approved by the ethic committee of the university hospital

- 346 Essen on 12. May 1999. All participants gave their written informed consent before
- 347 participating in the studies.

348 **Participant protection**

- 349 Data is anonymized according to the data protection act, individual participants are not
- 350 identifiable.

351 Competing interests

352 The authors have declared that no competing interests exist.

353 Authors' contributions

- Research idea and study design: SS, AS; data acquisition: KJ, MF, DZ, RE;
- analysis/interpretation: SS, BK; statistical analysis: SS; supervision or mentorship: AS, BK.
- 356 Each author contributed important intellectual content during manuscript drafting or revision
- and agrees to be personally accountable for the individual's own contributions and to ensure
- that questions pertaining to the accuracy or integrity of any portion of the work, even one in
- 359 which the author was not directly involved, are appropriately investigated and resolved,
- 360 including with documentation in the literature if appropriate.

361 Acknowledgement

- 362 The authors express their gratitude to all study participants of the Heinz Nixdorf Recall
- 363 (HNR) Study, the personnel of the HNR study center and the EBT-scanner facilities, the
- investigative group and all former employees of the HNR study. The authors also thank the
- 365 Advisory Board of the HNR Study: T. Meinertz, Hamburg, Germany (Chair); C. Bode,
- 366 Freiburg, Germany; P.J. de Feyter, Rotterdam, Netherlands; B. Güntert, Hall i.T., Austria; F.
- 367 Gutzwiller, Bern, Switzerland; H. Heinen, Bonn, Germany; O. Hess (†), Bern, Switzerland; B.
- 368 Klein (†), Essen, Germany; H. Löwel, Neuherberg, Germany; M. Reiser, Munich, Germany;
- 369 G. Schmidt (†), Essen, Germany; M. Schwaiger, Munich, Germany; C. Steinmüller, Bonn,
- 370 Germany; T. Theorell, Stockholm, Sweden; and S.N Willich, Berlin, Germany.

medRxiv preprint doi: https://doi.org/10.1101/2021.12.23.21268085; this version posted December 23, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Literature:

- 1. Bruck K, Stel VS, Gambaro G, et al. CKD Prevalence Varies across the European General Population. *J Am Soc Nephrol.* 2016;27(7):2135-2147.
- 2. Baumeister SE, Boger CA, Kramer BK, et al. Effect of chronic kidney disease and comorbid conditions on health care costs: A 10-year observational study in a general population. *Am J Nephrol.* 2010;31(3):222-229.
- 3. Stevens PE, Levin A. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med.* 2013;158(11):825-830.
- 4. Delanaye P, Jager KJ, Bokenkamp A, et al. CKD: A Call for an Age-Adapted Definition. *J Am Soc Nephrol.* 2019;30(10):1785-1805.
- 5. Greer RC, Crews DC, Boulware LE. Challenges perceived by primary care providers to educating patients about chronic kidney disease. *J Ren Care*. 2012;38(4):174-181.
- 6. Wagner M, Wanner C, Schich M, et al. Patient's and physician's awareness of kidney disease in coronary heart disease patients a cross-sectional analysis of the German subset of the EUROASPIRE IV survey. *BMC Nephrol.* 2017;18(1):321.
- 7. Stolpe S, Bock E, Scholz C, Stang A, Blume C. Unentdeckte Beeinträchtigung der Nierenfunktion - ein Feld mit hoher Relevanz für die Public Health Community. 2018.
- 8. Tuot DS, Plantinga LC, Hsu CY, et al. Chronic kidney disease awareness among individuals with clinical markers of kidney dysfunction. *Clin J Am Soc Nephrol.* 2011;6(8):1838-1844.
- 9. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. *Eur Heart J*. 2020;41(2):255-323.
- 10. Guidelines AHATFoCP. Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology. In. *J Am Coll Cardiol.* Vol 712018:e:127-e248.
- 11. NICE. Guideline. In. *Hypertension in adults: Diagnosis and management*: National Institute for Health and Care Excellence; 2019.
- 12. Kostev K, Lucas A, Jacob L. Frequency of Blood Pressure and Estimated Glomerular Filtration Rate Testing in Type 2 Diabetes Mellitus: A Retrospective Study with 43,509 Patients. *Exp Clin Endocrinol Diabetes.* 2019;127(7):455-460.
- 13. Jacob L, Seitz F, Kostev K. Frequency of blood pressure and estimated glomerular filtration rate monitoring in patients affected by hypertension: a retrospective study with 176 565 patients in Germany. *Blood Press Monit.* 2018;23(2):85-90.
- Rheinberger M, Jung B, Segiet T, et al. Poor risk factor control in outpatients with diabetes mellitus type 2 in Germany: The DIAbetes COhoRtE (DIACORE) study. *PLoS One.* 2019;14(3):e0213157.
- 15. Tuot DS, Plantinga LC, Judd SE, et al. Healthy behaviors, risk factor control and awareness of chronic kidney disease. *Am J Nephrol.* 2013;37(2):135-143.
- 16. Tonelli M, Dickinson JA. Early Detection of CKD: Implications for Low-Income, Middle-Income, and High-Income Countries. *J Am Soc Nephrol.* 2020;31(9):1931-1940.
- 17. Toussaint N. Screening for early chronic kidney kisease. 2012.
- 18. Galbraith LE, Ronksley PE, Barnieh LJ, et al. The See Kidney Disease Targeted Screening Program for CKD. *Clin J Am Soc Nephrol.* 2016;11(6):964-972.
- 19. Manns B, Hemmelgarn B, Tonelli M, et al. Population based screening for chronic kidney disease: cost effectiveness study. *BMJ.* 2010;341:c5869.
- 20. Yarnoff BO, Hoerger TJ, Simpson SK, et al. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. *BMC Nephrol.* 2017;18(1):85.

- 21. Echouffo-Tcheugui JB, Kengne AP. Risk models to predict chronic kidney disease and its progression: a systematic review. PLoS medicine. 2012;9(11):e1001344.
- 22. Fraccaro P, van der Veer S, Brown B, et al. An external validation of models to predict the onset of chronic kidney disease using population-based electronic health records from Salford, UK. BMC Med. 2016;14:104.
- 23. Mogueo A, Echouffo-Tcheugui JB, Matsha TE, Erasmus RT, Kengne AP. Validation of two prediction models of undiagnosed chronic kidney disease in mixed-ancestry South Africans. BMC Nephrol. 2015;16:94.
- 24. Kearns B, Gallagher H, de Lusignan S. Predicting the prevalence of chronic kidney disease in the English population: a cross-sectional study. BMC Nephrol. 2013;14:49.
- 25. Bang H, Vupputuri S, Shoham DA, et al. SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med. 2007;167(4):374-381.
- 26. Kshirsagar AV, Bang H, Bomback AS, et al. A simple algorithm to predict incident kidney disease. Arch Intern Med. 2008;168(22):2466-2473.
- 27. Kwon KS, Bang H, Bomback AS, et al. A simple prediction score for kidney disease in the Korean population. Nephrology (Carlton). 2012;17(3):278-284.
- 28. Thakkinstian A, Ingsathit A, Chaiprasert A, et al. A simplified clinical prediction score of chronic kidney disease: a cross-sectional-survey study. BMC Nephrol. 2011;12:45.
- 29. Stang A, Moebus S, Dragano N, et al. Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: identifiability of phone numbers as the major determinant of response. Eur J Epidemiol. 2005;20(6):489-496.
- 30. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis. 2010;55(4):622-627.
- 31. Trocchi P, Girndt M, Scheidt-Nave C, Markau S, Stang A. Impact of the estimation equation for GFR on population-based prevalence estimates of kidney dysfunction. BMC Nephrol. 2017;18(1):341.
- 32. Tjur T. Coefficients of Determination in Logistic Regression Models-A New Proposal: The Coefficient of Discrimination. Am Stat. 2009;63(4):366-372.
- 33. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128-138.
- 34. Tangri N, Stevens LA, Griffith J, et al. A predictive model for progression of chronic kidney disease to kidney failure. Jama. 2011;305(15):1553-1559.
- 35. Tangri N, Ferguson T, Komenda P. Pro: Risk scores for chronic kidney disease progression are robust, powerful and ready for implementation. Nephrol Dial Transplant. 2017;32(5):748-751.
- 36. Berns JS. Routine Screening for CKD Should Be Done in Asymptomatic Adults ... Selectively. Clin J Am Soc Nephro. 2014;9(11):1988-1992.
- 37. Komenda P, Rigatto C, Tangri N. Screening Strategies for Unrecognized CKD. Clin J Am Soc Nephrol. 2016;11(6):925-927.
- 38. Vart P, Reijneveld SA, Bultmann U, Gansevoort RT. Added Value of Screening for CKD among the Elderly or Persons with Low Socioeconomic Status. Clin J Am Soc Nephro. 2015;10(4):562-570.
- 39. Harward DH, Bang H, Hu Y, Bomback AS, Kshirsagar AV. Evaluation of the Scored Questionnaire to Identify Individuals with Chronic Kidney Disease in a Community-based Screening Program in Rural North Carolina. J Community Med Health Educ. 2014;4(Suppl 2):007.
- 40. Lerner B, Desrochers S, Tangri N. Risk Prediction Models in CKD. Semin Nephrol. 2017;37(2):144-150.
- 41. Moons KG, Altman DG, Vergouwe Y, Royston P. Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ. 2009;338:b606.

- 42. Schuit E, Groenwold RH, Harrell FE, Jr., et al. Unexpected predictor-outcome associations in clinical prediction research: causes and solutions. CMAJ. 2013;185(10):E499-505.
- 43. Bang H, Mazumdar M, Kern LM, Shoham DA, August PA, Kshirsagar AV. Validation and comparison of a novel screening guideline for kidney disease: KEEPing SCORED. Arch Intern Med. 2008;168(4):432-435.
- 44. Janssen KJ, Moons KG, Kalkman CJ, Grobbee DE, Vergouwe Y. Updating methods improved the performance of a clinical prediction model in new patients. J Clin Epidemiol. 2008;61(1):76-86.

Supporting information

Supporting file includes:

- S1: Equations for eGFR estimation used in the analyses
- S2: Equation of prediction models externally validated
- S3: Fig S1: Calibration of the six models using CKD-Epi equation to define CKD 3-5
- S4: Performance indicators for selected CKD risk models; CKD defined as eGFR <60ml/min/1.73m² calculated with FAS and MDRD equation

S5: Diagnostic criteria for prediction models for various threshold for CKD defined by MDRD and FAS equations ((sensitivity, specificity and predictive values and the respective proportions of expected to observed cases and 95%-confidence intervals).